Deals
Pfizer CEO Looks for More Deals as Drugmaker Mulls Split
- Managers still targeting decision about split by end of 2016
- CEO seeking experimental drugs that are close to hit market
Can Pfizer's Big Beat Lead to an Innovative Spilt?
This article is for subscribers only.
Pfizer Inc. is interested in buying drugmakers with products that are close to hitting the market, while considering a split of the business in the wake of failed takeover attempts of Allergan Plc and AstraZenca Plc.
“At this stage I would chose a late-stage asset because I think we have a lot of products in our own internal portfolio that are going to require substantial research and development funds,” Chief Executive Officer Ian Read said in an interview.